Published in Curr Biol on August 10, 2004
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol (2010) 3.61
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
The AID/APOBEC family of nucleic acid mutators. Genome Biol (2008) 3.25
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res (2006) 3.15
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res (2010) 2.96
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med (2006) 2.83
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 2.68
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog (2006) 2.61
Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog (2007) 2.52
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res (2005) 2.43
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Host restriction factors blocking retroviral replication. Annu Rev Genet (2008) 2.41
Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol (2006) 2.40
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses. PLoS Genet (2007) 2.33
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J Virol (2005) 2.20
Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol (2005) 2.17
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol (2005) 2.04
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci U S A (2005) 1.95
Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood (2007) 1.93
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol (2007) 1.91
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol (2010) 1.85
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol (2008) 1.85
Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol (2005) 1.84
Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A (2008) 1.83
All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res (2007) 1.79
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol (2006) 1.75
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol (2008) 1.74
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol (2006) 1.69
Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem (2008) 1.68
Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res (2006) 1.67
Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure (2010) 1.65
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A (2012) 1.65
Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol (2008) 1.63
An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol (2009) 1.62
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J Virol (2005) 1.56
Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol (2005) 1.55
Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J Virol (2007) 1.53
Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol (2008) 1.53
Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res (2006) 1.53
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology (2007) 1.52
Restriction of foamy viruses by APOBEC cytidine deaminases. J Virol (2006) 1.52
Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology (2009) 1.51
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol (2008) 1.51
Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol (2008) 1.50
A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J Biol Chem (2009) 1.49
Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol (2007) 1.47
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res (2006) 1.46
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol (2010) 1.40
Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One (2009) 1.39
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol (2009) 1.38
Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol (2011) 1.38
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathog (2017) 1.38
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol (2008) 1.37
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology (2008) 1.36
The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol (2010) 1.34
Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol (2008) 1.33
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology (2007) 1.33
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
APOBECs and virus restriction. Virology (2015) 1.27
APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology (2009) 1.27
APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol (2006) 1.26
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem (2010) 1.24
Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol (2008) 1.24
Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One (2008) 1.23
Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol (2010) 1.22
Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol (2010) 1.20
Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem (2006) 1.19
Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells. J Virol (2011) 1.18
Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol (2011) 1.18
The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. J Virol (2006) 1.17
Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J Biol Chem (2009) 1.17
A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem (2010) 1.17
Stably expressed APOBEC3F has negligible antiviral activity. J Virol (2010) 1.15
Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J Virol (2008) 1.15
AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature (2002) 7.12
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet (2013) 3.94
APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol (2010) 3.61
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol (2004) 3.59
E2-2 protein and Fuchs's corneal dystrophy. N Engl J Med (2010) 3.31
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res (2010) 2.96
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem (2006) 2.86
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature (2008) 2.80
Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature (2011) 2.71
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem (2005) 2.62
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Immunity through DNA deamination. Trends Biochem Sci (2003) 2.39
Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res (2012) 2.29
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci U S A (2005) 2.00
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol (2008) 1.85
Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure (2010) 1.65
An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol (2009) 1.62
Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Lett (2007) 1.62
APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58
Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet (2010) 1.57
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol (2008) 1.51
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res (2006) 1.46
The use of tinted contact lenses in the management of achromatopsia. Optometry (2007) 1.45
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Biol Chem (2010) 1.38
Pillars article: AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. 2002. 418: 99-103. J Immunol (2015) 1.38
Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem (2012) 1.38
Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci U S A (2007) 1.35
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol (2010) 1.35
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol (2012) 1.28
Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. Elife (2013) 1.28
Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol (2011) 1.25
Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol (2008) 1.24
APOBEC3B and AID have similar nuclear import mechanisms. J Mol Biol (2012) 1.22
Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev (2006) 1.21
A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J Biol Chem (2010) 1.17
APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood (2012) 1.15
MDM2 can interact with the C-terminus of AID but it is inessential for antibody diversification in DT40 B cells. Mol Immunol (2005) 1.13
Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure (2013) 1.13
Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol (2010) 1.12
AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Res (2009) 1.09
Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle (2013) 1.07
Contribution of copy number variation in the regulation of complement activation locus to development of age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.07
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer (2014) 1.07
Competition of Escherichia coli DNA polymerases I, II and III with DNA Pol IV in stressed cells. PLoS One (2010) 1.07
The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One (2007) 1.04
HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces. AIDS Res Hum Retroviruses (2012) 1.03
Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G. PLoS Pathog (2012) 1.02
Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry (2012) 1.00
Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J Biol Chem (2013) 0.99
Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein. J Biol Chem (2011) 0.98
Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine (2005) 0.98
The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. J Mol Biol (2013) 0.97
Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol (2008) 0.96
Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J Virol (2009) 0.95
DNA-dependent protein kinase inhibits AID-induced antibody gene conversion. PLoS Biol (2007) 0.94
Unique DNA repair gene variations and potential associations with the primary antibody deficiency syndromes IgAD and CVID. PLoS One (2010) 0.93
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res (2015) 0.93
Directed DNA deamination by AID/APOBEC3 in immunity. Curr Biol (2006) 0.91
Copy number variation in the complement factor H-related genes and age-related macular degeneration. Mol Vis (2011) 0.90
Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem (2012) 0.90
Efficient herpes simplex virus 1 replication requires cellular ATR pathway proteins. J Virol (2012) 0.89
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol (2009) 0.89
Atomic force microscopy studies of APOBEC3G oligomerization and dynamics. J Struct Biol (2013) 0.88
Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G. J Virol (2013) 0.88
Small molecules that inhibit Vif-induced degradation of APOBEC3G. Virol J (2014) 0.86
Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F. J Mol Biol (2013) 0.84
Herpes simplex virus type 1 single strand DNA binding protein and helicase/primase complex disable cellular ATR signaling. PLoS Pathog (2013) 0.82
CEM-T4 cells do not lack an APOBEC3G cofactor. PLoS Pathog (2009) 0.82
Dancin' deaminase. Nat Struct Mol Biol (2006) 0.80
Canine distemper outbreak in pet store puppies linked to a high-volume dog breeder. J Vet Diagn Invest (2012) 0.80
The interaction between AID and CIB1 is nonessential for antibody gene diversification by gene conversion or class switch recombination. PLoS One (2010) 0.79
Retinal and pontine striations: neurodiagnostic signs of autosomal recessive spastic ataxia of Charlevoix-Saguenay. J Neuroophthalmol (2014) 0.78
D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B. Virology (2013) 0.78
APOBEC3 inhibits DEAD-END function to regulate microRNA activity. BMC Mol Biol (2013) 0.77